PET-CT, CTA, prosthetic heart valve, endocarditis
Conditions
Interventions
PET-CT and CTA
Sponsors
University Medical Center Utrecht, Erasmus Medical Center Rotterdam
Eligibility
Inclusion criteria
Inclusion criteria: Age ≥ 50 years Patients after uncomplicated PHV implantation in aortic position (mechanical and biological PHVs). Normal routine follow up TTE (standardly performed 5 days after operation). With no signs of obstruction, endocarditis or significant paravalvular leakages. Group 1: 5 (± 1) weeks after PHV implantation (n=25). Group 2: 12 (± 2) weeks after PHV implantation (n=25). Group 3 : 12 (± 2) months after PHV implantation (n=25). Inclusion in group 3: only in case of ≥ 1 patients with post-operative moderate/severe uptake (QVSH score) in group 2. Weight < 110 kg
Exclusion criteria
Exclusion criteria: Known contrast allergy Known renal impairment (GFR<60) Diabetes Mellitus Mild contractile dysfunction of the left and/or right ventrical (Eyeballing, Ejection fraction <45 %, TAPSE <14 mm) Active cardiac decompensation Uncontrolled cardiac arrhythmias Suspicion on active endocarditis Previous participation in scientific studies using radiation. (Possible) pregnancy in pre-menopausal women above 50 years not on reliable birth control therapy. Other contraindications for contrast use according the standard daily clinical routine according to the protocol “Protocol preventie contrastreactie en contrastnefropathie” by the department of radiology UMCU or EMC Use of pericardial patches and re-operation of aortic PHV in past medical history Contraindication for Computed Tomography Angiography according the standard daily clinical routine Refusal to be informed about potential additional CTA or FDG-PET findings If already included in group 1 (early post operative phase), patients cannot be included in group 2 or 3 (late post operative phase).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Qualification Visual Score for Hypermetabolism (QVSH) - Standardized Uptake Value (SUV) ratio (quantitative measurement) | — |
Secondary
| Measure | Time frame |
|---|---|
| - Feasibility of hybrid fusion (diagnostic CTA and PET): percentage of patients for which it is possible to fuse FDG-PET images and cardiac CTA images - Artefacts (region, extend and type and location) during assessment with FDG-PET/CTA will be described | — |
Contacts
Public ContactA.M. Harder, den
University Medical Center Utrecht, Department of Radiology P.O. Box 85500, E01.132
Outcome results
None listed